BioAge Labs

BioAge develops small-molecule therapies for metabolic disease by targeting biology associated with human aging. The company’s current lead focus is inflammasome-driven inflammation, with programs designed to translate biomarker and human-data insights into medicines suitable for broad cardiometabolic populations.

BioAge is focused on metabolic disease and cardiometabolic risk, including inflammation-linked risk-factor profiles commonly seen in obesity. The company has also signaled interest in adjacent indications where systemic inflammation is a driver of disease biology.

BGE-102 is BioAge’s lead program. It is an oral, brain-penetrant small-molecule NLRP3 inhibitor in Phase I (SAD/MAD). BioAge has described initial development in obesity and cardiovascular risk-factor populations and has also disclosed an expansion of BGE-102 into diabetic macular edema as an additional clinical direction. Other programs are earlier stage and have been described at a higher level without the same degree of asset-by-asset public detail.

January 2026: BioAge reported additional positive interim Phase I data for BGE-102, including biomarker reductions consistent with anti-inflammatory activity in participants with elevated cardiovascular risk.

January 2026: BioAge also disclosed an expansion of BGE-102 development into diabetic macular edema as an ophthalmology proof-of-concept step.
December 2025: BioAge reported positive interim Phase I data for BGE-102 and continued Phase I execution.

BioAge’s recent updates have focused on interim Phase I biomarker readouts for BGE-102, including reductions in inflammation markers in participants with elevated baseline risk. The company has positioned these findings as supportive of advancement into patient studies designed to test clinical relevance in cardiometabolic populations.

Near-term milestones include completing Phase I data readouts for BGE-102 and initiating a Phase IIa study path in 2026, alongside clarifying the initial patient-study designs and endpoints for both cardiometabolic and ophthalmology proof-of-concept plans.

BioAge is led by a CEO with a data-driven drug discovery background and operates with an organization structured for biomarker-forward early clinical development, reflecting a strategy that prioritizes rapid translation from mechanistic readouts to patient proof-of-concept.